Profil
Laurence Reilly is Senior Independent Non-Executive Director at ImmuPharma Plc since 2023.
Former roles include Chief Scientific Officer & Vice President at Avillion LLP, Chief Medical Officer at Cellectar Biosciences, Inc., and Vice President-Research & Investments at Royalty Pharma Plc.
Education includes a doctorate from The University of Liverpool and a graduate degree from De Montfort University.
Postes actifs de Laurence Reilly
| Sociétés | Poste | Début |
|---|---|---|
| IMMUPHARMA PLC | Directeur/Membre du Conseil | 11/08/2023 |
Anciens postes connus de Laurence Reilly
| Sociétés | Poste | Fin |
|---|---|---|
Avillion LLP
Avillion LLP BiotechnologyHealth Technology Engages in clinical development of therapeutics | Directeur Technique/Scientifique/R&D | - |
| ROYALTY PHARMA PLC | Corporate Officer/Principal | - |
| CELLECTAR BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Laurence Reilly
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
The University of Liverpool
The University of Liverpool Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
De Montfort University
De Montfort University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ImmuPharma Plc
ImmuPharma Plc Pharmaceuticals: OtherHealth Technology Discovers and develops pharmaceutical drugs | Health Technology |
Avillion LLP
Avillion LLP BiotechnologyHealth Technology Engages in clinical development of therapeutics | Health Technology |
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer | Health Technology |
Royalty Pharma Plc
Royalty Pharma Plc Pharmaceuticals: MajorHealth Technology Buys and operates a portfolio of biopharmaceutical royalties | Health Technology |
















